Enisamium Reduces Influenza Virus Shedding and Improves Patient Recovery by Inhibiting Viral RNA Polymerase Activity

Infections with respiratory viruses constitute a huge burden on our health and economy. Antivirals against some respiratory viruses are available, but further options are urgently needed. Enisamium iodide (laboratory code FAV00A, trade name Amizon) is an antiviral, marketed in countries of the Commo...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2021-03, Vol.65 (4)
Main Authors: Te Velthuis, Aartjan J W, Zubkova, Tatiana G, Shaw, Megan, Mehle, Andrew, Boltz, David, Gmeinwieser, Norbert, Stammer, Holger, Milde, Jens, Müller, Lutz, Margitich, Victor
Format: Article
Language:English
Subjects:
Antiviral Agents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infections with respiratory viruses constitute a huge burden on our health and economy. Antivirals against some respiratory viruses are available, but further options are urgently needed. Enisamium iodide (laboratory code FAV00A, trade name Amizon) is an antiviral, marketed in countries of the Commonwealth of Independent States for the treatment of viral respiratory infections, but its clinical efficacy and mode of action are not well understood. In this study, we investigated the efficacy of enisamium in patients aged between 18 and 60 years with confirmed influenza virus and other viral respiratory infections. Enisamium treatment resulted in reduced influenza virus shedding (at day 3, 71.2% in the enisamium group tested negative versus 25.0% in placebo group [  
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.02605-20